SCHEMBL20554146

SCHEMBL20554146

N#Cc1cc(Oc2ccnc(Cl)c2)nc2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.39
PIN1 Q13526 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 5/20 0.38
HTT P42858 3/20 0.38
HPGD P15428 2/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 2/20 0.36
RAF1 P04049 1/20 0.36
MAP2K1 Q02750 1/20 0.36
GRM5 P41594 1/20 0.36
KDM4E B2RXH2 2/20 0.36
TRPA1 O75762 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
PPARG P37231 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30132577 1.00 L3MBTL1 (0.39) L3MBTL1PIN1CYP1A2CYP2C9CYP2C19
SCHEMBL30132618 0.82 BLM (0.40) L3MBTL1CYP1A2CYP2C9LMNAALDH1A1
SCHEMBL20554621 0.82 BLM (0.40) L3MBTL1CYP1A2CYP2C9LMNAALDH1A1
SCHEMBL20554711 0.82 L3MBTL1 (0.51) L3MBTL1PIN1CYP1A2CYP2C9CYP2C19
SCHEMBL30132564 0.82 L3MBTL1 (0.51) L3MBTL1PIN1CYP1A2CYP2C9CYP2C19
SCHEMBL20554074 0.79 LOXL2 (0.44) L3MBTL1CYP1A2CYP2C9CYP2C19LMNA
SCHEMBL190220 0.74 POLB (0.50) PIN1ALDH1A1SMN1; SMN2POLB
SCHEMBL30132636 0.73 L3MBTL1 (0.48) L3MBTL1LMNAALDH1A1HTTHPGD
SCHEMBL20554867 0.73 L3MBTL1 (0.48) L3MBTL1LMNAALDH1A1HTTHPGD
SCHEMBL2185260 0.73 ALDH1A1 (0.50) L3MBTL1CYP1A2CYP2C9CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110770211-B Alpha, beta unsaturated amide compound 协和麒麟株式会社 2023-09-19 CN disclosed
CN-108430972-B Alpha, beta-unsaturated amide compound 协和麒麟株式会社 2022-12-27 CN disclosed
US-11447471-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-09-20 US disclosed
US-11332455-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-05-17 US disclosed
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-12-09 US disclosed
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-05-27 US disclosed
US-10787428-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2020-09-29 US disclosed
EP-3712129-A1 ALPHA, BETA-UNSATURATED AMIDE COMPOUND Kyowa Kirin Co., Ltd. (JP) 2020-09-23 EP disclosed
CN-110770211-A α unsaturated amide compound 协和麒麟株式会社 2020-02-07 CN disclosed
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-01-10 US disclosed
EP-3401309-A1 a, ß UNSATURATED AMIDE COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2018-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, RXRA L3MBTL1 2435/4885PIN1 3712/4885CYP1A2 998/4885
US-11447471-B2 α,β-unsaturated amide compound NR1H2, RXRA, RXRB L3MBTL1 2437/4885PIN1 3722/4885CYP1A2 965/4885
US-10787428-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 L3MBTL1 3176/4885PIN1 3580/4885CYP1A2 883/4885
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 L3MBTL1 3129/4885PIN1 3547/4885CYP1A2 923/4885
US-11332455-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 L3MBTL1 3176/4885PIN1 3580/4885CYP1A2 883/4885
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 L3MBTL1 3129/4885PIN1 3547/4885CYP1A2 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.